MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Recruiting
Phase 3
Interventional Study
Ovarian Neoplasm Epithelial
Fallopian Tube Neoplasms
Peritoneal Neoplasms
High-grade Serous Ovarian Carcinoma (HGSOC)
Low-grade Serous Ovarian Carcinoma (LGSOC)
Ovarian Endometrioid Carcinoma
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 540 (estimated)
- Sponsor
- Swiss GO Trial Group · Research network
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of the participants will receive to the st…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients must be ≥ 18 years of age
* Willing and able to attend the visits and to understand all study-related procedures.
* Primary, newly diagnosed FIGO Stage II to IV and histologically confirmed low or high grade serous or endometrioid epithelial ovarian/fallopian tube/per…
Contacts